What ₹20,000 for Three Months of Endocrinologist-Led Care Actually Buys

A three-month quote of around ₹20,000 is a common number in Indian medical weight management, and it usually buys care rather than medicine: three to four clinician consultations, at least one broad metabolic panel, often a body-composition measurement, and structured follow-up in between.

Bought separately at listed 2026 rates, those same components come to roughly ₹14,000 to ₹24,000, so a ₹20,000 package sits inside that range rather than below it. What such a fee does not reliably include is medication. What follows is where the money goes, what moves it, and what to make a provider itemise before paying.

Key Takeaways:

• A ₹20,000 three-month package is not a markup on components a person could buy separately. Assembled at 2026 listed prices, the same components cost roughly ₹14,000 to ₹24,000.
• Medicine is not reliably inside a quoted care fee. "₹20,000 for three months" and "₹20,000 all-inclusive" are different products, and the gap between them is not small.
• The semaglutide patent expired on 20 March 2026, after which generics launched almost immediately. A cost breakdown written before mid-2026 is already wrong on the medicine line.
• Standard Indian health insurance excludes obesity and weight-control treatment. For most privately paying adults in 2026, the entire care and medicine budget comes out of pocket.
• The most reliable test of whether a clinical structure is genuine versus cosmetic is whether the physician changes anything based on what the tests show.

Snapshot, and its expiry date: Every figure below is a listed Indian price observed between March and August 2026. This category is repricing faster than almost anything else in Indian private healthcare, and the single largest reason is that the Indian patent on semaglutide expired on 20 March 2026, after which generic versions launched almost immediately. A cost breakdown written in 2025 is already wrong. Assume this one will be wrong too, and treat the structure below as more durable than the numbers in it.

Clinician-supervised weight management, stripped of packaging, is four things a provider has to pay for: doctor time, laboratory work, measurement, and the contact that happens between appointments. Every quote in this category is some combination of those four, priced at some level of seniority and frequency.

• Clinician consultations: One longer first consultation plus 2 to 3 shorter follow-ups. Listed cost: ₹5,000 to ₹7,000.
• Blood work: One broad metabolic panel, sometimes a repeat or a targeted monitoring panel. Listed cost: ₹4,000 to ₹6,000.
• Body composition: One DEXA or equivalent scan, where the clinician orders it. Listed cost: ₹3,000 to ₹5,000.
• Between-visit contact: Nutrition and activity coaching, app access, messaging or check-in calls. Listed cost: ₹2,000 to ₹6,000.

These are assembled ranges rather than observed package prices. Each row is built from what individual items list for in 2026, and the consultation row in particular is derived from per-visit endocrinology fees applied across three to four visits, not from a quoted three-month figure. No provider was found publishing this breakdown, which is part of the point.

Two things follow from that arithmetic. A ₹20,000 three-month fee is not, on its face, a markup on components a reader could buy individually for a fraction of the price, which is the usual suspicion. And the spread between the bottom and the top of the assembled range is around ₹10,000, wide enough that two providers quoting the same number can be selling materially different things.

The number that does not appear in the table is medication, and it is left out deliberately rather than for space. Whether it belongs inside the fee is a separate question, addressed further down.

Private endocrinology consultations in large Indian cities list at roughly ₹800 to ₹2,500 per visit as of 2026, with obesity-focused endocrinologists in metros such as Mumbai clustering nearer ₹1,500 to ₹2,200. A first consultation is normally the longest and the dearest of the series, because it is where the history, the existing prescriptions and the previous investigations are gone through.

Four variables move that per-visit figure, and they move it in predictable directions. Seniority and specialty matter most: a consultation with a DM-qualified endocrinologist prices above one with a general physician or a diabetologist, which prices above a dietitian session run under clinician oversight. City tier is next, with metro private practice at the top of the band. Mode matters, since a video consultation carries no premises cost and is frequently priced below the same clinician's in-person rate. Frequency is the multiplier that turns a per-visit price into a package price.

That last variable is where a quote becomes hard to compare. Three consultations at ₹2,000 and six at ₹1,000 produce the same line item and a very different experience of being looked after.

It is also why the word "endocrinologist-led" is worth interrogating rather than accepting. In the middle of the market, the common design is a protocol run by physicians, dietitians and coaches with periodic specialist oversight. That is a legitimate model and not the same thing as seeing a specialist at every appointment.

Bundled metabolic panels at national diagnostic chains list in the ₹2,000 to ₹4,000 range as of 2026, covering fasting glucose, HbA1c, a lipid profile, liver and kidney markers, thyroid function, and in the broader packages fasting insulin and inflammatory markers. Panels marketed specifically for monitoring people on GLP-1 treatment appeared through 2025 and 2026 and list from roughly ₹2,800 upward.

Diagnostic breadth is the single most reliable predictor of where a package sits in the price range, because it is the layer providers cut first. Three elements determine whether the diagnostic component is useful:

• What tests are included: A basic panel and a broad one can differ by a factor of two in cost and by considerably more in what they are capable of showing.
• How many times: A programme that tests once at baseline and one that re-tests at twelve weeks are buying different amounts of the same thing.
• Whether anything changes based on them: The most reliable test of whether a structure is genuine versus cosmetic is whether the physician changes anything based on what the tests show.

Body composition sits alongside the blood work and is more variable still. A whole-body DEXA scan in a metro private facility runs roughly ₹3,000 to ₹5,000 per scan, while bioimpedance measurement taken in-clinic often carries no separate charge at all because the provider already owns the machine. A package that includes "monthly body-composition review" may mean either. Asking which is a fair question and the answer changes the value of the line by several thousand rupees.

Publicly posted three-month programme fees in India cluster into three bands once medication is excluded. The bands below describe market structure rather than any particular provider, and the inclusions are typical rather than universal.

• Around ₹7,000 to ₹15,000: General physician led, frequently video-first. Typically includes 2 to 3 doctor consultations, one basic lab panel, a dietitian plan, and app or messaging check-ins.
• Around ₹15,000 to ₹30,000: Endocrinologist or obesity-focused physician, hybrid online and clinic. Typically includes 3 to 4 specialist consultations, at least one comprehensive metabolic panel, a structured nutrition plan, monthly body-composition or vitals review, and messaging access.
• ₹30,000 and above: Hospital-based or boutique obesity service. Typically includes high-frequency consultations, weekly coaching, repeated advanced panels and scans, and sometimes bundled investigations such as sleep studies.

A ₹20,000 quote sits in the middle band. What that band reasonably promises is genuine specialist involvement at some defined frequency, at least one broad laboratory work-up, and structured follow-up. What it does not promise is unlimited in-person visits, repeated advanced imaging, or a named specialist personally handling every contact.

The narrow cost point is that the à la carte route is available, is not dramatically cheaper at listed prices, and puts the co-ordination work on the reader.

One structural caveat applies to the whole table. Providers publish headline prices and inclusion lists, but almost none publish the split between doctor fees, coaching, laboratory contracts and margin. Component apportionment inside a package is therefore inference from public component prices, not disclosure.

Medication is the line item that decides what a quoted number means, and Indian programmes handle it in three different ways. Some charge a care-only fee and leave the patient to fill the prescription at any pharmacy. Some charge an all-inclusive subscription in which the platform arranges dispensing through a partner pharmacy. Some charge a programme fee, negotiate pharmacy rates, and still bill the medicine as a separate line.

Nothing in Indian law obliges any particular one of those. GLP-1 medicines are Schedule H drugs, which means they are dispensed only against a valid prescription and cannot be advertised to the public, and retail sale sits under a state sale licence. Those rules constrain how a medicine is sold and promoted rather than whether its cost may be folded into a service fee.

Two practical consequences matter to anyone reading a quote. First, "₹20,000 for three months" and "₹20,000 for three months, all inclusive" are not variations on a price, they are different products, and the gap between them is not small. Second, where a programme states that medication is included, the effective medicine cost inside the package is generally not publicly verifiable. Platforms claiming member or contracted pricing do not usually disclose the rate, so an all-inclusive figure cannot be decomposed from outside.

The March 2026 patent expiry is what makes this worth checking now rather than assuming. For several years the medicine line was, for many people, the largest single item in a monthly weight-management budget, and any comparison of providers was really a comparison of what they charged for the drug.

Generic entry and subsequent repricing across the category through the first half of 2026 changed the proportions materially. The consequence is not that any particular product became affordable, which is a clinical and personal judgement rather than a general one, but that a total quoted before mid-2026 tells you very little about a total quoted now. What any individual should be taking, if anything, is a decision for a registered medical practitioner who has assessed them, and no cost analysis substitutes for that.

Endocrinologist scarcity is the standard justification for the top of the consultation band, and the number usually cited to support it does not survive checking. The widely repeated claim that India has around 650 endocrinologists traces to uncited web essays and popular articles rather than to a register count or a published workforce study. It should not be repeated, including by anyone using it to explain a price.

What can be said is weaker and more honest. Commercial doctor-directory datasets suggest upwards of 2,000 practising endocrinologists nationally by 2025, but those rest on scraped listings rather than a government register. Professional society membership offers a second proxy: the Endocrine Society of India reports growth from a few hundred members in the 1990s to roughly 1,000 in recent anniversary material, without claiming to cover every practising specialist. No unified public register exists from which a national headcount could be drawn.

Taken together, the evidence supports real scarcity relative to a population of India's size, and does not support any precise figure. Scarcity of that kind is a plausible part of why senior metro endocrinologists price at the top of the private band, and it is also why intermediate-priced programmes are built around physician-led protocols with specialist oversight rather than around specialist time throughout. A provider quoting a specific national headcount as a reason for its pricing is quoting something nobody has established.

Standard Indian retail health insurance covers hospitalisation rather than chronic outpatient treatment, and obesity or weight-control treatment appears among the standard policy exclusions in wordings filed with IRDAI, outside narrow criteria for bariatric surgery. Consultations and laboratory panels done as outpatient care are similarly uncovered in most base policies.

Medication prescribed for weight loss is, on the available India-specific insurance analysis as of 2026, almost never reimbursed under individual retail policies. Use labelled for diabetes sometimes attracts partial reimbursement, and then usually through an outpatient rider or a corporate group plan rather than a base policy. Beyond that general position the detail is genuinely opaque: formulary status and prior-authorisation rules vary by insurer and by corporate plan, and are typically visible only inside policy documents and internal circulars rather than in public summaries.

For a privately paying adult in India in 2026, the safe planning assumption is that the entire care budget and the entire medication budget come out of pocket. Anyone with an employer plan or an outpatient rider should check the specific wording rather than the general rule, because the general rule is where the exceptions are hiding.

A quoted package price is only as informative as the breakdown behind it. Before paying, ask a provider for answers to five questions in writing:

• Who are the clinicians? How many consultations, with whom by name and qualification, and in which mode?
• What does the diagnostic line include? Which laboratory panel, how many times over the three months, and does the fee cover the repeat?
• How is body composition measured? DEXA or in-clinic bioimpedance, and how often?
• What does between-visit contact consist of? Who is on the other end of it, and what triggers an escalation?
• Is any medication cost inside this figure? If so, at what dose band and for how long?

A provider that answers all five in writing is quoting a price. A provider that will not put a figure or an inclusion list in writing before a sales call is doing something else, and withheld pricing sits alongside several other patterns worth recognising in red flags before paying.

Cost is the easiest thing to compare in this category and the least useful thing to compare alone. A cheaper package is not worse care and a dearer one is not better care. Each is a different bundle of clinician time, diagnostic breadth and follow-up, and the right bundle depends on a clinical picture that no price list contains. If a quote is being weighed for care delivered remotely, it is worth understanding what a remote consultation is legally permitted to do before assessing what it is worth, which is set out in how online supervision works. What any individual actually needs remains a judgement for a registered medical practitioner who has examined them.

Looking for a programme where the cost structure is transparent before you sign? At Voy, what is included in your plan is specified before you begin. See how it works.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.